Liza Varghese, MD
Rheumatology · Crestview Hills, KYNPI 1952306193
Payments from drug & device makers
Across 697 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- UCB, Inc.$6K
- Sobi, Inc$4K
- AbbVie$3K
- Amgen$3K
- Novartis$923
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 74 | $8,414 |
| UCB, Inc. | 73 | $5,695 |
| Sobi, Inc | 6 | $3,636 |
| AbbVie | 156 | $3,057 |
| Amgen(2 entities) | 134 | $2,889 |
| Novartis | 53 | $923 |
| Lilly USA, LLC | 31 | $594 |
| AstraZeneca(2 entities) | 23 | $544 |
| E.r. Squibb & Sons, L.L.C. | 32 | $511 |
| Pfizer | 24 | $420 |
| Mallinckrodt Hospital Products Inc. | 13 | $320 |
| Janssen Scientific Affairs, LLC | 3 | $297 |
| GSK | 30 | $293 |
| Aurinia Pharma U.S., Inc. | 6 | $217 |
| Genentech USA, Inc. | 7 | $140 |
| Radius Health, Inc. | 5 | $98 |
| ANI Pharmaceuticals, Inc. | 4 | $97 |
| Fresenius Kabi USA, LLC | 4 | $69 |
| Boehringer Ingelheim | 3 | $51 |
| Pacira Therapeutics, Inc. | 3 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Vertex | 1 | $25 |
| Hikma Pharmaceuticals USA | 2 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Invivyd Inc | 1 | $18 |
| Sanofi | 1 | $16 |
| Merck | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $11 |
How this compares
$28,520 in reported general payments places this provider in the 80th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Crestview Hills
- Christopher ColglazierCrestview Hills$22K
- Kerrin BurteCrestview Hills$16K
- Abraham TacangCrestview Hills$9K
- Ann GeorgeCrestview Hills$8K
- Magdalena WiniarskaCrestview Hills$5K
- Mazen ElyanCrestview Hills$4K
- Sarah KellerCrestview Hills$3K
- Joseph TemmingCrestview Hills$2K
- Nicola JacksonCrestview Hills$2K
- Zehra KazmiCrestview Hills$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.